Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$9.42 USD

9.42
363,633

+0.03 (0.32%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $9.42 0.00 (0.00%) 5:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

by Zacks Equity Research

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

Zacks Equity Research

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

by Zacks Equity Research

Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.

Zacks Equity Research

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

by Zacks Equity Research

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Zacks Equity Research

Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025

by Zacks Equity Research

PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.

Zacks Equity Research

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -21.74% and 86.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

by Zacks Equity Research

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.

Zacks Equity Research

Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus

by Zacks Equity Research

PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.

Zacks Equity Research

Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

by Zacks Equity Research

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.

Zacks Equity Research

Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well

by Zacks Equity Research

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.